Eitzen Chemical ASA – Ratio Change

DR CUSIP: 282610104
DR ISIN: US2826101048
DR Ticker Symbol: EITZY

Please be advised that The Bank of New York Mellon, as Depositary, will change the ratio of the Eitzen Chemical ASA, Depositary Receipt (“DR”) program from 1 DS representing 1,000 Common shares to 1 DS representing 10 Common shares, effective February 12, 2013.

Please note the following:

Old DR Ratio: 1 DS : 1,000 Common shares
New DR Ratio: 1 DS : 10 Common shares
Effective date for DR ratio change: February 12, 2013

Please note: A ratio change may impact the fees payable by ADR investors.

As there are no ADRs outstanding in the ADR facility, no distribution will be made. Our ADR inventory will automatically represent the new ratio. The CUSIP will remain the same.

Books will be closed from February 7, 2013 and will reopen on February 13, 2013 for Issuance and Cancellation transactions.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

**New York**
Ravi Davis
Vice President
+1 212 815-4245
Ravi.davis@bnymellon.com

**London**
Damon Rowan
Vice President
+44 207 964 6527
damon.rowan@bnymellon.com

**Hong Kong**
Joe Oakenfold
Vice President
+852 2 840 9717
joe.oakenfold@bnymellon.com

BNY Mellon may pay a rebate to brokers in connection with the deposit of shares for the issuance of unsponsored DRs; broker may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon may also transact with affiliate brokers and dealers.

This information and data is provided for general purposes only; it is not investment advice and should not be used for any investment decisions nor trading purposes. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this announcement and shall have no liability for investment or other decisions based hereon, including market values loss on the sales or purchase of securities or other instruments or obligations. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.